Literature DB >> 31131511

Coordinatively Unsaturated Fe3+ Based Activatable Probes for Enhanced MRI and Therapy of Tumors.

Peisen Zhang1,2, Yi Hou1, Jianfeng Zeng3,4, Yingying Li1,2, Zihua Wang1, Ran Zhu3,4, Tiancong Ma1,2, Mingyuan Gao1,2,3,4.   

Abstract

Exogenous FeIII can be used for cancer magnetic resonance (MR) imaging and potentially for cancer treatment by a ferroptosis pathway or photothermal ablation. To achieve this, effective and accurate delivery of FeIII to cancerous sites is critical, requiring a balance of release kinetics of Fe3+ in tumorous and normal tissues. A nanoprobe is described consisting of upconversion luminescence (UCL) nanoparticles as a core and a coordinatively unsaturated FeIII -containing Fe3+ /gallic acid complex as a shell. Owing to the introduction of an unsaturated coordination structure, FeIII in the nanoprobe can be released only in the tumor microenvironment in response to the lightly acidic pH. The multiple UCLs are used for quantitatively visualizing the release of Fe3+ in vivo, whilst the release resultant serves as a photothermal agent. This nanoprobe exhibited ligand-free tumor targeting ability, activatable MR imaging performance, and efficacious therapeutic effects against tumors in vivo.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  UCL; activated MRI; combined therapy; coordinatively unsaturated Fe3+; ferroptosis

Year:  2019        PMID: 31131511     DOI: 10.1002/anie.201904880

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  17 in total

Review 1.  The Advances and Biomedical Applications of Imageable Nanomaterials.

Authors:  Xiaohong Xiang; Doudou Shi; Jianbo Gao
Journal:  Front Bioeng Biotechnol       Date:  2022-07-05

Review 2.  Ferroptosis: Final destination for cancer?

Authors:  Zeng Ye; Wensheng Liu; Qifeng Zhuo; Qiangsheng Hu; Mengqi Liu; Qiqing Sun; Zheng Zhang; Guixiong Fan; Wenyan Xu; Shunrong Ji; Xianjun Yu; Yi Qin; Xiaowu Xu
Journal:  Cell Prolif       Date:  2020-02-25       Impact factor: 6.831

3.  Editorial: Target-Triggered Nanoparticles for Tumor Diagnosis and Therapy.

Authors:  Yi Hou; Xiaoling Wei; Yunfeng Yan; Jing Hao
Journal:  Front Chem       Date:  2021-04-12       Impact factor: 5.221

Review 4.  Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors.

Authors:  Yan Yang; Saisai Yue; Yuanyuan Qiao; Peisen Zhang; Ni Jiang; Zhenbo Ning; Chunyan Liu; Yi Hou
Journal:  Front Chem       Date:  2021-04-12       Impact factor: 5.221

5.  Visualizing the Potential Impairment of Polymyxin B to Central Nervous System Through MR Susceptibility-Weighted Imaging.

Authors:  Ni Zhang; Lichong Zhu; Qiuhong Ouyang; Saisai Yue; Yichun Huang; Shuang Qu; Runwei Li; Yuanyuan Qiao; Man Xu; Fangfei He; Bin Zhao; Lai Wei; Xiaoai Wu; Peisen Zhang
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

Review 6.  Fenton/Fenton-like metal-based nanomaterials combine with oxidase for synergistic tumor therapy.

Authors:  Wei Cao; Mengyao Jin; Kang Yang; Bo Chen; Maoming Xiong; Xiang Li; Guodong Cao
Journal:  J Nanobiotechnology       Date:  2021-10-16       Impact factor: 10.435

Review 7.  Nanotechnology-enhanced immunotherapy for metastatic cancer.

Authors:  Peisen Zhang; Junli Meng; Yingying Li; Chen Yang; Yi Hou; Wen Tang; Kevin J McHugh; Lihong Jing
Journal:  Innovation (Camb)       Date:  2021-10-14

Review 8.  Internally Responsive Nanomaterials for Activatable Multimodal Imaging of Cancer.

Authors:  Zachary T Rosenkrans; Carolina A Ferreira; Dalong Ni; Weibo Cai
Journal:  Adv Healthc Mater       Date:  2020-07-21       Impact factor: 9.933

Review 9.  Nanoparticle-Based Activatable Probes for Bioimaging.

Authors:  Tiancong Ma; Tian Xia
Journal:  Adv Biol (Weinh)       Date:  2021-01-04

Review 10.  Metal-Coordinated Supramolecular Self-Assemblies for Cancer Theranostics.

Authors:  Jiating Xu; Jun Wang; Jin Ye; Jiao Jiao; Zhiguo Liu; Chunjian Zhao; Bin Li; Yujie Fu
Journal:  Adv Sci (Weinh)       Date:  2021-06-18       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.